For decades, the human niche for viruses related to smallpox has remained mostly empty. Since eradicating smallpox, only rare ...
Framingham Union Hospital will close one of its neonatal intensive care units for newborns with critical health needs on June ...
Clinical Trials Arena on MSN5d
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trialAstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 ...
AZD0780 30mg taken daily demonstrated robust, dose-dependent, placebo-adjusted reductions in LDL-C from baseline to week 12 ...
These two general immune response findings, immune response at baseline and increasing immune response over time, were also observed in the Phase IIb clinical trial for HLA-A*02 only patients. These ...
GRI Bio Inc.’s oral version of tazarotene is showing phase IIa promise in idiopathic pulmonary fibrosis (IPF). The peek at interim safety with the compound, a RAR-βɣ dual agonist designed to inhibit ...
Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...
INDIANAPOLIS — GeniPhys, a preclinical-stage company developing regenerative collagen polymeric biomaterials for soft tissue restoration, has been awarded a $500,000 National Science Foundation (NSF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback